Announcement PDF ASX / MEDIA ANNOUNCEMENT EVP R&D DR MITCHELL GLASS DISCUSS WITH BRR MEDIA DATA FROM THE PHASE II CLINICAL TRIAL OF INV102 (NADOLOL) IN SMOKING CESSATION Brisbane, Australia and Delaware, United States, 6 October 2015: Australian respiratory technology company Invion Limited (ASX: IVX) is delighted to invite investors to listen to Invion’s Dr Mitchell Glass discuss the results of the Phase II clinical trial of INV102 (nadolol) in patients trying to quit smoking, following the successful conclusion of the study. In this audiocast, Dr Glass discusses the following:  Phase 2 trial data demonstrates INV102 treated smokers were more likely to stop smoking completely or dramatically reduce the number of cigarettes smoked;  Data demonstrates that INV102 is a safe and effective treatment for patients with chronic bronchitis who are enrolled in smoking cessation programs;  Invion is preparing an FDA submission during Q4 2015 for End of Phase 2 Meeting request; and  New data paves the way for INV102 to be developed as a novel inhaled treatment for chronic airway diseases including asthma, COPD and cystic fibrosis. To access the audiocast, please visit this link: http://www.brrmedia.com/event/140433 -----------------------------------------About Invion Limited Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory and autoimmune disease. The Group has three drug assets in development across four development programs. INV102 (nadolol) is a beta adrenergic biased ligand targeted to reverse mucous metaplasia in the airway epithelium treat chronic inflammatory airway diseases. A large phase II study in smoking cessation reported successful data in Q4 2015 and feasibility for an inhaled version of the drug is well-progressed with 3M Drug Delivery Systems. A phase II asthma study funded by the US NIH is ongoing. INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. An approved oral therapy, Invion is developing an inhaled version of the drug. INV103 (ala-Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion is an ASX listed company (ASX:IVX), with its clinical headquarters in Delaware, USA. FOR MORE INFORMATION CONTACT Managing Director and CEO: Dr Greg Collier. P: 07 3295 0500 greg.collier@inviongroup.com Invion Limited ABN 76 094 730 417 GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com